Remacemide

Remacemide
Systematic (IUPAC) name
	N-(1-methyl-1,2-diphenylethyl)glycinamide
Clinical data
Pregnancy cat.	?
Legal status	?
Identifiers
CAS number	128298-28-2
ATC code	None
PubChem	CID 60511
UNII	EH6763C1IC
Synonyms	2-amino-N-[1,2-di(phenyl)propan-2-yl]acetamide
Chemical data
Formula	C17H20N2O
Mol. mass	268.3535 g/mol
(what is this?) (verify);

From Wikipedia, the free encyclopedia

Jump to: navigation, search

Remacemide is a drug which acts as a low-affinity NMDA antagonist with sodium channel blocking properties.^[1] It has been studied for the treatment of acute ischemic stroke^[2] and epilepsy^[3].

[edit] References

^ Wright, LK; Pearson, EC; Hammond, TG; Paule, MG (2007 May-Jun). "Behavioral effects associated with chronic ketamine or remacemide exposure in rats". Neurotoxicol Teratol 29 (3): 348–59. doi:10.1016/j.ntt.2006.12.004. PMID 17291718.
^ Dyker, AG; Lees, KR (1999). "Remacemide Hydrochloride: A Double-Blind, Placebo-Controlled, Safety and Tolerability Study in Patients With Acute Ischemic Stroke". Stroke 30 (9): 1796–1801. doi:10.1161/01.STR.30.9.1796. PMID 10471426.
^ Wesnes, KA; Edgar, C; Dean, AD; Wroe, SJ (2009). "The cognitive and psychomotor effects of remacemide and carbamazepine in newly diagnosed epilepsy". Epilepsy & behavior : E&B 14 (3): 522–8. doi:10.1016/j.yebeh.2008.11.012. PMID 19111629.

This psychedelics, dissociatives and deliriants-related article is a stub. You can help Wikipedia by expanding it.